Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-26
2011-07-26
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S490000, C548S491000
Reexamination Certificate
active
07985764
ABSTRACT:
It was found that a compound according to the following formula:or a pharmaceutically acceptable salt thereof, has a strong antagonism for both the 5-HT2Band 5-HT7receptors. In addition, the compound shows good pharmacological action as compared to antagonists selective for only one of these receptors. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2Breceptor and 5-HT7receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).
REFERENCES:
patent: 5852046 (1998-12-01), Lang et al.
patent: 6358992 (2002-03-01), Pamukcu et al.
patent: 6440988 (2002-08-01), Craig
patent: 6514968 (2003-02-01), TenBrink
patent: 6534535 (2003-03-01), Zhu et al.
patent: 2008/0171788 (2008-07-01), Akuzawa et al.
patent: 2010/0168096 (2010-07-01), Yamada et al.
patent: 68844/94 (1995-02-01), None
patent: 0 622 356 (1994-11-01), None
patent: 0 639 573 (1995-02-01), None
patent: 1 716 867 (2006-11-01), None
patent: 1 728 784 (2006-12-01), None
patent: 1 852 129 (2007-11-01), None
patent: 1 923 387 (2008-05-01), None
patent: 07-010839 (1995-01-01), None
patent: 07-145149 (1995-06-01), None
patent: 8-48671 (1996-02-01), None
patent: 10-67682 (1998-03-01), None
patent: 10-114654 (1998-05-01), None
patent: 2005-162657 (2005-06-01), None
patent: 2005162657 (2005-06-01), None
patent: 96/32379 (1996-10-01), None
patent: 99/20599 (1999-04-01), None
patent: 01/12600 (2001-02-01), None
patent: 2004/108688 (2004-12-01), None
Kitano et al. Chemical and Pharmaceutical Bulletin (1999), 47(11), 1538-1548.
Whorwell et al., “Bladder smooth muscle dysfunction in patients with irritable bowel syndrome”, Gut, vol. 27 (1986) 1014-17.
Hoyer, et al., VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin); Pharmacological Reviews, vol. 46, No. 2 (1994) 157-203.
Bearcroft, et al., “Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study”, Gut, vol. 42 (1998) 42-6.
Kim, et al., “Serotonin: A Mediator of the Brain—Gut Connection”, The American Journal of Gastroenterology, vol. 95, No. 10 (2000) 2698-709.
Talley, “Pharmacological Therapy for the Irritable Bowel Syndrome”, The American Journal of Gastroenterology, vol. 98, No. 4 (2003) 750-58.
Wyatt, et al., “Indentification of Potent and Selective Oxytocin Antagonists. Part 1: Indole and Benzofuran Derivatives”, Bioorganic & Medicinal Chemistry Letters, vol. 12, No. 10 (2002) 1399-1404.
DePonti, et al., “Irritable Bowel Syndrome, New Agents Targeting Serotonin Receptor Subtypes”, Drugs, vol. 61, No. 3 (2001) 317-32.
Carter, et al., “Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum”, European Journal of Pharmacology, vol. 280 (1995) 243-50.
Liu, et al., “Expression patterns of 5-HT7 receptor isoforms in the rat digestive tract”, Life Sciences, vol. 69 (2001) 2467-75.
Borman, et al., “Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine”, British Journal of Pharmacology, vol. 114 (1995) 1525-27.
Vourloumis, et al., “Solid-phase synthesis of benzimidazole libraries biased for RNA targets”, Tetrahedron Letters, vol. 44, No. 14 (2003) 2807-11.
Lopez-Rodriguez, et al., “Benzimidazole Derivatives. 3. 3D-QSAR/CoMFA Model and Computational Simulation for the Recognition of 5-HT4 Receptor Antagonists”, J. Med. Chem., vol. 45, No. 22 (2002) 4806-15.
Kuroita, et al., “Design and Synthesis of 6-Chloro-3,4-dihydro-4-methyl-2H-1,4-benzoxazine-8-carboxamide Derivatives as Potent Serotonin-3 (5-HT3) Receptor Antagonist”, Chem. Pharm. Bull., vol. 44, No. 4 (1996) 756-64.
Borman, et al., “5-HT2B receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro”, British Journal of Pharmacology, vol. 135 (2002) 1144-51.
CAS Registry No. 312604-61-8; Jul. 24, 2007.
CAS Registry No. 515828-64-5; Feb. 7, 2006.
CAS Registry No. 338984-26-2; Sep. 6, 2007.
CAS Registry No. 309727-87-5; Apr. 9, 2007.
CAS Registry No. 846563-08-4; Apr. 9, 2007.
CAS Registry No. 846563-01-7; Apr. 9, 2007.
CAS Registry No. 878688-87-0; Apr. 9, 2007.
CAS Registry No. 846563-24-4; Sep. 6, 2007.
CAS Registry No. 895121-54-7; Sep. 6, 2007.
CAS Registry No. 895117-17-6; Sep. 6, 2007.
CAS Registry No. 895097-35-5; Sep. 6, 2007.
CAS Registry No. 895122-22-2; Sep. 6, 2007.
CAS Registry No. 895122-18-6; Sep. 6, 2007.
CAS Registry No. 895122-14-2; Sep. 6, 2007.
CAS Registry No. 895122-06-2; Sep. 6, 2007.
CAS Registry No. 895119-58-1; Sep. 6, 2007.
CAS Registry No. 895119-53-6; Sep. 6, 2007.
CAS Registry No. 895119-48-9; Sep. 6, 2007.
CAS Registry No. 895119-38-7; Sep. 6, 2007.
CAS Registry No. 895119-23-0; Sep. 6, 2007.
CAS Registry No. 895119-18-3; Sep. 6, 2007.
CAS Registry No. 895119-08-1; Sep. 6, 2007.
CAS Registry No. 895100-05-7; Sep. 6, 2007.
CAS Registry No. 895099-04-4; Sep. 6, 2007.
CAS Registry No. 895098-99-4; Sep. 6, 2007.
CAS Registry No. 895098-94-9; Sep. 6, 2007.
CAS Registry No. 895098-89-2; Sep. 6, 2007.
CAS Registry No. 895121-82-1; Sep. 6, 2007.
CAS Registry No. 895121-66-1; Sep. 6, 2007.
CAS Registry No. 895121-14-9; Sep. 6, 2007.
CAS Registry No. 895119-83-2; Sep. 6, 2007.
CAS Registry No. 895118-43-1; Sep. 6, 2007.
CAS Registry No. 895118-03-3; Sep. 6, 2007.
CAS Registry No. 895117-98-3; Sep. 6, 2007.
CAS Registry No. 895117-93-8; Sep. 6, 2007.
CAS Registry No. 895117-88-1; Sep. 6, 2007.
CAS Registry No. 895117-83-6; Sep. 6, 2007.
CAS Registry No. 895117-59-6; Sep. 6, 2007.
CAS Registry No. 895116-57-1; Sep. 6, 2007.
CAS Registry No. 895099-84-0; Sep. 6, 2007.
CAS Registry No. 895099-24-8; Sep. 6, 2007.
CAS Registry No. 895098-39-2; Sep. 6, 2007.
CAS Registry No. 895098-30-3; Sep. 6, 2007.
CAS Registry No. 895098-26-7; Sep. 6, 2007.
CAS Registry No. 895098-13-2; Sep. 6, 2007.
CAS Registry No. 895098-08-5; Sep. 6, 2007.
CAS Registry No. 895098-04-1; Sep. 6, 2007.
CAS Registry No. 895098-00-7; Sep. 6, 2007.
CAS Registry No. 895097-96-8; Sep. 6, 2007.
CAS Registry No. 895097-88-8; Sep. 6, 2007.
CAS Registry No. 895097-84-4; Sep. 6, 2007.
CAS Registry No. 895097-63-9; Sep. 6, 2007.
CAS Registry No. 895096-80-7; Sep. 6, 2007.
CAS Registry No. 895120-70-4; Sep. 6, 2007.
CAS Registry No. 895098-21-2; Sep. 6, 2007.
CAS Registry No. 895098-17-6; Sep. 6, 2007.
CAS Registry No. 895097-92-4; Sep. 6, 2007.
CAS Registry No. 895096-32-9; Sep. 6, 2007.
Tuladhar, et al., “5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum”, British Journal of Pharmacology, vol. 138 (2003) 1210-14.
CAS Registry No. 895118-33-9; Sep. 6, 2007.
CAS Registry No. 895118-28-2; Sep. 6, 2007.
CAS Registry No. 895118-18-0; Sep. 6, 2007.
CAS Registry No. 895118-13-5; Sep. 6, 2007.
CAS Registry No. 895118-08-8; Sep. 6, 2007.
Patani, et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev., vol. 96 (1996) 3147-76.
Theoharides, et al., “Interstitial cystitis: bladder pain and beyond”, Expert Opin. Pharmacother., vol. 9, No. 17 (2008) 2979-94.
Akuzawa Shinobu
Kaga Daisuke
Kaku Hidetaka
Seo Ryushi
Yamada Hiroyoshi
Astellas Pharma Inc.
Fitzpatrick ,Cella, Harper & Scinto
Habte Kahsay T
LandOfFree
Amide derivative or salt thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amide derivative or salt thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide derivative or salt thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2693749